Thesis icon

Thesis

Dissecting the immune environment in glioblastoma

Abstract:

Glioblastoma (GBM) is the most common primary brain tumour in adults. Unfortunately, it is also the most malignant, conferring a median survival of only 6 months, increasing to 14-24 months with maximal therapy. Despite much effort, there have been relatively little effective advances made for the treatment of GBM in the last decade. Immunotherapy, especially checkpoint inhibition, has revolutionised the management of some previously untreatable cancers, such as metastatic melanoma. Howeve...

Expand abstract

Actions


Authors


More by this author
Division:
MSD
Department:
RDM
Role:
Author

Contributors

Role:
Supervisor
ORCID:
0000-0003-0040-3793
More from this funder
Programme:
CRUK Clinical Research Training Fellowship
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford
Language:
English
Keywords:
Subjects:
Deposit date:
2021-02-03

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP